Abstract

PHARMACOLOGY OF DOSTARLIMAB: A REVIEW

Arnab Roy*

ABSTRACT

Dostarlimab is a humanised anti-PD-1 immunoglobulin (Ig G4) monoclonal antibody (mAb) that binds to the PD-1 receptor with high affinity and efficiently blocks interactions with the PD-1 ligands PD-L1 and PD-L2. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. T-cell proliferation and cytokine production are inhibited when tumour expressed ligands PD-L1 and PD-L2 bind to the PD-1 receptor.

Keywords: Dostarlimab, PD-1 immunoglobulin, T-cell proliferation.